Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.81 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692642 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL304308 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL302999 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL302998 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL4344462 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| Water SCHEMBL15421412 | 0.98 | ADRB3 (0.96) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL6539097 | 0.93 | ADRB3 (0.87) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL6539102 | 0.93 | ADRB3 (0.87) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| Hydrochloric Acid SCHEMBL6540037 | 0.93 | ADRB3 (0.86) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| Hydrochloric Acid SCHEMBL6540028 | 0.93 | ADRB3 (0.86) | ADRB3ADRB2ADRB1CYP2D6ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715637-B | Glucokinase activators and methods of use thereof | 百时美施贵宝公司 | 2022-04-05 | — | — | CN | disclosed |
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | US | disclosed |
| US-10335380-B2 | Compounds suitable for the treatment of myeloproliferative neoplasms as well as methods for the diagnosis/prognosis of myeloproliferative neoplasms | CNIC Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III (ES) | 2019-07-02 | — | — | US | disclosed |
| EP-3487862-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | Bristol-Myers Squibb Company (US) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018017910-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
| EP-2850073-B1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20160250163-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AS WELL AS METHODS FOR THE DIAGNOSIS/PROGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS | CNIC Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III (ES) | 2016-09-01 | — | — | US | disclosed |
| EP-2994119-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (ES) | 2016-03-16 | — | — | EP | disclosed |
| US-20150374655-A1 | BETA-3 ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY HYPERTENSION | HOSPITAL CLINIC DE BARCELONA (ES) | 2015-12-31 | — | — | US | disclosed |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012277-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| WO-2008137435-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1070046-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | ADRB3 143/4885ADRB2 83/4885ADRB1 48/4885 |
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | ADRB3 1906/4885ADRB2 1960/4885ADRB1 1250/4885 |
| US-10335380-B2 | Compounds suitable for the treatment of myeloproliferative neoplasms as well as methods for the diagnosis/prognosis of myeloproliferative neoplasms | NES, ADRB3, ADRB1 | ADRB3 2/4885ADRB2 5/4885ADRB1 3/4885 |
| US-20160250163-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AS WELL AS METHODS FOR THE DIAGNOSIS/PROGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS | NES, ADRB3, ADRB1 | ADRB3 2/4885ADRB2 5/4885ADRB1 3/4885 |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | ADRB3 156/4885ADRB2 70/4885ADRB1 56/4885 |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | ADRB3 159/4885ADRB2 90/4885ADRB1 56/4885 |
| US-20150374655-A1 | BETA-3 ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY HYPERTENSION | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885ADRB1 3/4885 |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCK, GCKR, GALK1 | ADRB3 1906/4885ADRB2 1960/4885ADRB1 1250/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | ADRB3 189/4885ADRB2 86/4885ADRB1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.